激素替代疗法是否会影响子宫内膜癌幸存者的预后？系统评价。
Does Hormone Replacement Therapy Impact the Prognosis in Endometrial Cancer Survivors? A Systematic Review.
机构信息
Department of Maternal and Child Health and Urological Sciences, University of Rome "Sapienza," Umberto I Hospital, Rome, Italy.
Department of Maternal and Child Health and Urological Sciences, University of Rome "Sapienza," Umberto I Hospital, Rome, Italy,
出版信息
Oncology. 2020;98(4):195-201. doi: 10.1159/000505427. Epub 2020 Feb 7.
PURPOSE
The objective of this study was to evaluate the impact of hormone replacement therapy (HRT) on the prognosis in endometrial cancer (EC) survivors.
METHODS
The research was conducted using the following electronic databases: MEDLINE (PubMed), Web of Science, ClinicalTrial.gov, and Cochrane Library. We performed a review of studies published from January 1986 to January 2019. We selected studies that included EC patients submitted to surgery with curative intent and postoperative use of HRT.
RESULT
Seven of 1,332 abstracts considered were eligible: 4 retrospective series, 1 prospective study, 1 randomized controlled trial, and 1 population study. Globally in the observed studies there was not a significant increase in the recurrence rate, measured by the relative risk, in the EC survivors using HRT compared with the controls in tumour stages I and II. The bias was that HRT was prescribed only to low-risk patients, who were young and had a low stage of disease.
CONCLUSION
This systematic review shows that HRT use had no negative effect on prognosis in EC survivors in tumour stages I and II.
目的
本研究旨在评估激素替代疗法（HRT）对子宫内膜癌（EC）幸存者预后的影响。
方法
本研究使用了以下电子数据库：MEDLINE（PubMed）、Web of Science、ClinicalTrials.gov 和 Cochrane Library。我们对 1986 年 1 月至 2019 年 1 月发表的研究进行了综述。我们选择了包括接受根治性手术和术后使用 HRT 的 EC 患者的研究。
结果
在考虑的 1332 篇摘要中有 7 篇符合条件：4 项回顾性系列研究、1 项前瞻性研究、1 项随机对照试验和 1 项人群研究。在观察到的研究中，总体上，与对照组相比，使用 HRT 的 I 期和 II 期 EC 幸存者的复发率（通过相对风险衡量）没有显著增加。偏倚在于 HRT 仅开给低风险患者，这些患者年轻且疾病处于低分期。
结论
本系统评价表明，在 I 期和 II 期的 EC 幸存者中，HRT 的使用对预后没有负面影响。
Zotero 插件